Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining

Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803, USA.
Molecular &amp Cellular Proteomics (Impact Factor: 6.56). 02/2008; 7(1):163-9. DOI: 10.1074/mcp.M700115-MCP200
Source: PubMed


Dissociable antibody microarray (DAMA) staining is a technology that combines protein microarrays with traditional immunostaining techniques. It can simultaneously determine the expression and subcellular location of hundreds of proteins in cultured cells and tissue samples. We developed this technology and demonstrated its application in identifying potential biomarkers for breast cancer. We compared the expression profiles of 312 proteins among three normal breast cell lines and seven breast cancer cell lines and identified 10 differentially expressed proteins by the data analysis program DAMAPEP (DAMA protein expression profiling). Among those proteins, RAIDD, Rb p107, Rb p130, SRF, and Tyk2 were confirmed by Western blot and statistical analysis to have higher expression levels in breast cancer cells than in normal breast cells. These proteins could be potential biomarkers for the diagnosis of breast cancer.

Download full-text


Available from: Wayne Zhou, Feb 27, 2015
  • Source
    • "Moreover, protein expression depends on different cellular and developmental conditions, as well as different cell types [43]. We used only one standard genomic sequence (UCSC hg19) and two different cell cultures not directly related to that genome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Proteogenomic mapping is an approach that uses mass spectrometry data from proteins to directly map protein-coding genes and could aid in locating translational regions in the human genome. In concert with the ENcyclopedia of DNA Elements (ENCODE) project, we applied proteogenomic mapping to produce proteogenomic tracks for the UCSC Genome Browser, to explore which putative translational regions may be missing from the human genome. Results We generated ~1 million high-resolution tandem mass (MS/MS) spectra for Tier 1 ENCODE cell lines K562 and GM12878 and mapped them against the UCSC hg19 human genome, and the GENCODE V7 annotated protein and transcript sets. We then compared the results from the three searches to identify the best-matching peptide for each MS/MS spectrum, thereby increasing the confidence of the putative new protein-coding regions found via the whole genome search. At a 1% false discovery rate, we identified 26,472, 24,406, and 13,128 peptides from the protein, transcript, and whole genome searches, respectively; of these, 481 were found solely via the whole genome search. The proteogenomic mapping data are available on the UCSC Genome Browser at Conclusions The whole genome search revealed that ~4% of the uniquely mapping identified peptides were located outside GENCODE V7 annotated exons. The comparison of the results from the disparate searches also identified 15% more spectra than would have been found solely from a protein database search. Therefore, whole genome proteogenomic mapping is a complementary method for genome annotation when performed in conjunction with other searches.
    BMC Genomics 02/2013; 14(1):141. DOI:10.1186/1471-2164-14-141 · 3.99 Impact Factor
    • "Zhou et al.[41] developed dissociable antibody microarray (DAMA) staining technology that combines protein microarrays with traditional immune-staining techniques and demonstrated its application in identifying potential biomarkers for breast cancer. DAMA can simultaneously determine the expression and subcellular location of hundreds of proteins in cultured cells and tissue samples. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There are more than 1.15 million cases of breast cancer diagnosed worldwide annually. At present, only small numbers of accurate prognostic and predictive factors are used clinically for managing the patients with breast cancer. DNA microarrays have the potential to assess the expression of thousands of genes simultaneously. Recent preliminary researches indicate that gene expression profiling based on DNA microarray can offer potential and independent prognostic information in patients with newly diagnosed breast cancer. In this paper, an overview upon the applications of microarray techniques in breast cancer is presented.
    03/2012; 4(1):21-6. DOI:10.4103/0975-7406.92726
  • Source
    • "Recently, some cell (9) and tissue microarrays (10) have emerged for the study of gene activity, protein expression, and cell-surface exploration and offer the potential to accelerate high-throughput functional genetic studies. A new focus in the cell microarray field has been the and adaptation of cell arrays for RNAi in a high-throughput format (11, 12) and the development of a new protein microarray platform, Dissociable Antibody MicroArray (DAMA) staining allowing global analysis of protein expression and subcellular localization (13). Although cell microarray technology has many possible experimental uses, several technical limitations need to be addressed before its full potential can be fulfilled (8, 12, 14). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, we describe a simple, rapid, specific, sensitive, and reliable method, the FICP method (Fluorescence Immunoassay for Cellular Protein detection) which is readily applicable to the detection of proteins directly on cells cultured in 96-well plates. In order to illustrate this method, we report on the detection of two different proteins, the cell cycle proteins cyclin D1 and p21(CIP1/WAF1), in untreated and 2-cyclopenten-1-one treated breast cancer cells. When the FICP method was compared with Western blot procedure, FICP was found to be superior for many characteristics. By using this method, we were able to quantify biological effects of a specific compound on protein levels in non-lysed cells and perform statistical analysis. Therefore, we believe this screening assay could be very useful for detecting poorly expressed proteins and for drug development.
    Biological Procedures Online 02/2008; 10(1):83-9. DOI:10.1251/bpo146 · 1.79 Impact Factor
Show more